Trump seeking economic deal with China as fresh trade talks loom- WSJ
LONDON - IQ-AI Limited has shared a significant update on its operations, highlighting advancements in artificial intelligence (AI) for neuro-oncology and progress in a Phase One clinical trial for glioblastoma treatment. The company's subsidiary, Imaging Biometrics, LLC (IB), is set to release a new version of IB Clinic, which includes an AI model that enhances diagnostic accuracy and speed in brain tumor imaging. This model, trained on a vast repository of brain tumor data, generates fractional tumor burden maps, aiding in the distinction between normal and unhealthy tissue.
The next release of IB Clinic will also feature IB Zero G, which utilizes a variation of the AI model for FDA approval readiness, and IB Nimble, a mobile app enabling patients to report symptoms in real-time. These developments are part of IQ-AI's commitment to leveraging AI for personalized medicine and improved patient outcomes.
Additionally, the company anticipates launching a new product using arterial spin labeling (ASL) technology, which has seen increased clinical demand, especially for stroke patient care. A new AI algorithm predicting the appearance of tumor cells before they become visible on standard imaging is also in the works, which could revolutionize treatment planning for cancer patients.
In the clinical arena, IQ-AI reports nearing completion of a Phase 1 trial of gallium maltolate (GaM) for relapsed glioblastoma, an aggressive brain tumor with limited survival rates. The trial has established the safety and tolerance of oral GaM, recommending a dose for future studies. Some patients have shown longer progression-free intervals compared to historical controls, prompting the development of a Phase 2 trial to determine the efficacy of GaM.
These developments underscore IQ-AI's role in advancing AI applications in healthcare and addressing the urgent need for effective glioblastoma treatments. The information is based on a press release statement from IQ-AI.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.